Korea Pharvis announced that Dr. 김민승, chief director of 아이니클리닉, delivered a lecture at the Retigen product launch event held in Hong Kong. The event was attended by approximately 100 local physicians.
Retigen is a 99.9% pure Type I collagen manufactured using the patented LTDP (Low-Temperature & Differential Pressure) sterilization process. It is an atelocollagen with the telopeptide proteins that can cause immune reactions removed.
Dr. Kim explained, "Directly injecting collagen into the skin maximizes the replenishing effect." Korea Pharvis plans to expand its business across Asia, starting with this entry into the Hong Kong market.
Source: 데일리팜